| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026091 | Ophthalmology | 2014 | 9 Pages |
Abstract
Slowing of progression of retinopathy by intensive treatment of glycemia was observed in ACCORD participants, whose average age and diabetes duration were 62 and 10 years, respectively, and who had cardiovascular disease or cardiovascular risk factors. The effect seemed stronger in patients with mild retinopathy. Similar slowing of progression was observed in patients treated with fenofibrate, with no effect observed with intensive blood pressure treatment. This is the second study to confirm the benefits of fenofibrate in reducing diabetic retinopathy progression, and fenofibrate should be considered for treatment of diabetic retinopathy.
Keywords
DMEWESDRFenofibrate Intervention and Event Lowering in DiabetesUKPDSACCORDPDRNPDRETDRSHbA1cDiabetic macular edemaAction to Control Cardiovascular Risk in Diabetesearly treatment diabetic retinopathy studynonproliferative diabetic retinopathyProliferative diabetic retinopathyFieldconfidence intervaldisc diameterdisc areaodds ratioGlycated hemoglobin
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Emily Y. MD, Matthew D. MD, Ronald P. MD, James F. MS, Letitia H. MS, Craig MD, Saul MD, David C. MD, PhD, Lawrence A. MD, Faramarz MD, PhD, Walter T. PhD,